ILARIS^®—Proven Efficacy

Complete Response, Sustained Response in Cryopyrin-Associated Periodic Syndromes (CAPS)

ILARIS® (canakinumab) is the first and only treatment approved for Familial Cold Autoinflammatory Syndrome ( FCAS) and Muckle-Wells Syndrome in both adult patients and pediatric patients aged 4 years and older.

ILARIS® has demonstrated proven efficacy by providing complete and sustained response in the treatment of patients suffering from CAPS.*

• 97% of CAPS patients achieved complete response by Week 8. 71% achieved complete response in just 7 days^1,2
• Complete response was defined as ratings of minimal or absent for physician's assessment of disease activity and assessment of skin disease and C-reactive protein (CRP) or serum amyloid A (SAA) values <10 mg/L^1,2
• A disease flare was defined as a CRP and/or SAA values >30 mg/L and either a score of mild or worse for disease activity or a score of minimal or worse for disease activity and skin disease^1,2

Click any of the following links to learn more about the proven efficacy of ILARIS^®:

• Complete Response
• Sustained Response

* The pivotal study included an 8-week open-label period (Part 1) and a 24-week randomized double-blind, placebo-controlled, withdrawal period (Part 2).¹